USANA Health Sciences, Inc. has entered into a First Amendment to its Third Amended and Restated Credit Agreement, dated as of September 30, 2026. The amendment modifies the terms of the revolving credit facility, which provides for up to $75,000,000 in borrowing capacity, potentially increasing to more than $200,000,000 upon request. The facility matures on June 27, 2030. Bank of America, N.A. serves as the administrative agent, swingline lender, and L/C issuer.
The amendment introduces a new minimum Consolidated EBITDA covenant. Beginning with the fiscal quarter ending October 3, 2026, the company must maintain Consolidated EBITDA of at least $100,000,000 for each trailing four-fiscal-quarter period. However, if the lenders' aggregate revolving exposure is $50,000,000 or less on the last day of the period, the minimum requirement drops to $70,000,000 for that period.
Other changes to the agreement include an increase in the general asset sale basket. The annual limit on the aggregate book value of property the Company and its subsidiaries may dispose of has been raised from $500,000 to $2,500,000. Additionally, a new section permits USANA Australia Pty, Ltd. to sell real property in Sydney, Australia and apply the net proceeds as it deems appropriate in its reasonable business judgment. Sale and leaseback transactions remain prohibited except as otherwise agreed by the Required Lenders or for dispositions permitted under the new section regarding the Sydney property.
